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1 Introduction
Malaria is a giant killer of children (over one million deaths per year (World Health
Organization, 2005)), imposes financial hardships on poor households and holds
back economic growth (World Health Organization, 1999). Symptoms of malaria
include fever, vomiting, shivering, anemia, retinal damage and coma (in severe
cases). Fever is the most common symptom of malaria and a vaccine that protected
against fever caused by malaria would be considered valuable for public health
(Moorthy, Reed and Smith, 2007). In this paper, we consider the challenges of
evaluating the efficacy of a malaria vaccine for preventing fever and study the prop-
erties of proposed approaches. An excellent reference for issues related to measur-
ing malaria vaccine efficacy, which this paper builds on, is the WHO Study Group
on Measures of Malaria Vaccine Efficacy report (Moorthy et al., 2007).
For a vaccine against an infectious agent, vaccine efficacy is defined roughly
as the reduction in incidence of the disease due to the infectious agent if everyone
took the vaccine (as opposed to a placebo) compared to the incidence of the disease
due to the infectious agent under the placebo (Hudgens, Gilbert and Self, 2004).
We give a precise causal definition of vaccine efficacy in Section 2.
Lachenbruch (1998) showed that if some people who do not have the dis-
ease due to the infectious agent are misclassified as having the disease due to the
infectious agent (i.e., specificity is less than 1), then vaccine efficacy estimates will
be biased downwards. This result poses challenges for estimating the efficacy of
a malaria vaccine. In settings in which the malaria parasite is endemic, it is diffi-
cult to determine whether a child suffering from a fever is suffering from a fever
caused by malaria parasites or a fever caused by a different infectious agent (Smith,
Schellenberg and Hayes, 1994). Fevers caused by malaria parasites often cannot
be distinguished on the basis of clinical features from fevers caused by other com-
mon childhood infections such as the common cold, pneumonia, influenza, viral
hepatitis or typhoid fever (Hommel, 2002; Koram and Molyneux, 2007). One aid
to deciding whether a fever is caused by malaria parasites or some other infection
is to measure the density of malaria parasites in the child’s blood. However, in ar-
eas where malaria is endemic, children can develop partial immunity to the toxic
effects of the parasites and can tolerate high parasite densities without developing
fever (Marsh, 2002; Boutlis, Yeo and Antsey, 2006). Thus, even if a child has fever
and has a high parasite density, the fever might still be caused by another infection.
In summary, there is no current perfect case definition of a fever caused by malaria
that has specificity 1 and sensitivity 1.
Two types of case definitions have been proposed for a fever caused by
malaria. One is an imperfect, but deterministic case definition. The WHO Study
Group on Measures of Malaria Vaccine Efficacy (Moorthy et al., 2007) recommends
1
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using as a case definition the conjunction of fever and a parasite density above a
certain cutoff. For example, Alonso et al. (2004) and Bejon et al. (2008) used a
cutoff of 2,500 parasites per µl. An alternative to an imperfect, deterministic case
definition of a malaria caused fever is to estimate the probability that a fever was
caused by malaria and use a probabilistic case definition. Smith, Schellenberg and
Hayes (1994) proposed a logistic regression approach for estimating the probability
that a child’s fever is malaria caused based on the child’s parasite density.
We compare in a simulation study the two approaches of using an imperfect,
deterministic case definition and a probabilistic case definition for estimating the
efficacy of a malaria vaccine. Rogers et al. (2006) and Smith (2007) have also
compared these two approaches. Our simulation study differs from theirs in that
we include in the simulation study model the phenomenon that fever due to an
infectious agent other than malaria parasites can reduce malaria parasite density
(Kwiatkowski, 1989; Long et al., 2001; Rooth and Bjorkman, 1992).
In Section 2, we provide a causal definition of vaccine efficacy in terms of
potential outcomes. In Section 3, we provide a causal diagram for how a vaccine
and other factors might affect fever. In Section 4, we discuss deterministic and
probabilistic case definitions of malaria caused fever and how they are used to esti-
mate vaccine efficacy. In Section 5, we compare the two approaches in a simulation
study. In Section 6, we provide discussion.
2 Potential Outcomes Definition of Vaccine Efficacy
Before defining vaccine efficacy, we first define what we mean by a fever that is
caused by malaria parasites. Let Y (p)i be child i’s potential fever outcome under the
placebo, Y (p)i = 1 if child i would have a fever if given the placebo and Y
(p)
i = 0 if
child i would not have a fever if given the placebo. Let Y (e)i be child i’s potential
fever outcome if malaria parasites were eradicated from the world. We say that a
child i who has a fever (under the placebo) has a malaria caused fever if the fever
would be eliminated by eradicating malaria, i.e., child i has a malaria caused fever
if Y (p)i = 1,Y
(e)
i = 0.
Let Y (v)i denote child i’s potential fever outcome if the child would take
the vaccine. We define the vaccine efficacy in a population as the reduction in the
number of children who would have fever if all children took the vaccine compared
to if all children took the placebo divided by the number of children who would
have a malaria caused fever if all children took the placebo:
V E =
P(Y (p)i = 1)−P(Y (v)i = 1)
P(Y (p)i = 1,Y
(e)
i = 0)
. (1)
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V E ranges from (−∞,1] with a V E of 1 indicating that the vaccine is as effective
as eradicating malaria, a V E greater than zero indicating that the vaccine is more
effective than the placebo, V E equal to zero indicating that the vaccine is equivalent
to the placebo and V E less than zero indicating that the vaccine is worse than the
placebo.
Another way to think about what V E is measuring is the following. Let RP
be the risk of fever under the placebo and RV be the risk of fever under the vaccine.
Then,
V E =
RP by all causes−RV by all causes
RP by malaria
,
where “by all causes,” we mean fever due to any cause, not just malaria. Consider
the assumption that the vaccine does not affect the probability of a fever from causes
other than malaria, i.e.,
Assumption (A-1):
P(Y (p)i = 1,Y
(e)
i = 1) = P(Y
(v)
i = 1,Y
(e)
i = 1).
Under (A-1), V E is equal to the effect of the vaccine on preventing malaria caused
fevers, which we denote by V E∗,
V E∗ =
RP by malaria−RV by malaria
RP by malaria
=
P(Y (p)i = 1,Y
(e)
i = 0)−P(Y (v)i = 1,Y (e)i = 0)
P(Y (p)i = 1,Y
(e)
i = 0)
. (2)
The equivalence of V E and V E∗ under assumption (A-1) is illustrated in Figure 1.
In Figure 1, V E = 0.7−0.50.5 = 0.4 and V E
∗ = 0.5−0.30.5 = 0.4.
We prefer to use V E rather than than V E∗ as our definition of vaccine ef-
ficacy because when assumption (A-1) fails and the vaccine affects the probability
of a non-malaria caused fever, we would like to include this effect in the mea-
sure of vaccine efficacy. A vaccine may cause fever by a variety of mechanisms
(Follmann, Fay and Proschan, 2009): (a) some vaccines are live but weakened
pathogens and the weakened pathogen can produce an infection in a weakened
host; (b) vaccine induced antibodies may enhance rather than reduce the chance
of disease (Burke, 1992); or (c) vaccines might induce an auto-immune reaction
which could hamper the ability of the immune system to fight disease. As an ex-
ample, consider a vaccine that prevents 10% of malaria caused fevers but causes
10{RP by malaria/(1−RP by all causes)}% of the people without fevers under the
placebo to have a fever. Then V E = 0 but V E∗= 0.1. This vaccine is not preventing
3
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Figure 1: Illustration of equivalence of V E and V E∗ under assumption (A-1).
fevers so we think V E = 0 is a better measure of the overall public health benefit of
the vaccine than V E∗ = 0.1.
A problem with both V E and V E∗ is that the denominator RP by malaria is
not identifiable without assumptions that go beyond just randomization of vaccine
and placebo; we discuss this nonidentifiability in Section 4.2. A quantity that is
identifiable from a randomized trial without further assumptions is the proportion
of all fevers that are prevented by the vaccine, which we denote by V E.All,
V E.All =
RP by all causes−RV by all causes
RP by all causes
=
P(Y (p)i = 1)−P(Y (v)i = 1)
P(Y (p)i = 1)
.
V E.All measures the impact of the vaccine on the trial population and is hence of
considerable interest. However, V E.All does not address the following question
that is addressed by V E: Is the vaccine preventing most malaria-caused fevers (V E
close to 1) or is there considerable room for improving the vaccine? For example,
suppose V E.All is 0.2. This could mean that the vaccine is not that effective and
could be considerably improved, or it could mean that the vaccine is very effec-
tive, preventing most malaria caused fevers, but that most fevers in the area are not
malaria caused. Another question of interest that requires knowing both V E and
V E.All is the following: What impact would we expect the vaccine to have on a
population in which malaria accounts for a different proportion of fevers than in the
trial population? Thus, both V E and V E.All are important quantities in assessing a
vaccine.
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3 Causal Diagram for the Effect of a Vaccine
To better understand the properties of different estimators of the efficacy of a malaria
vaccine, it is helpful to consider a causal diagram for how a vaccine and other causes
affect fever. Figure 2 depicts a causal diagram. The bottom row of the figure shows
how malaria parasites cause fever. First, a person needs to be bitten by a mosquito
carrying malaria parasites. When the mosquito takes its blood meal, it injects the
parasites into the person. The parasites then go to the person’s liver where they
develop and replicate. While in the liver, the parasites do not cause any clinical
symptoms. After several days, the parasites escape from the liver into the blood.
The parasites attack red blood cells, replicate within the red blood cells, burst the
red blood cells and attack further red blood cells. If uncontrolled, the parasites
will keep multiplying and keep destroying red blood cells, eventually causing se-
vere anemia. The parasite density measures the density of parasites in the blood at
a given time. As the parasites replicate, they are thought to release toxins which,
when built up enough, cause fever. For good discussion of the malaria parasite life
cycle and its effects on humans, see Warrell, Turner and Francis (2002) and Sinden
and Gilles (2002).
There are several types of vaccines being developed that aim to interrupt
various parts of how malaria parasites cause fever and other symptoms. One type of
vaccine (pre-erythrocytic) aims to attack the parasites in the liver and prevent them
from entering the blood. Another type of vaccine (erythrocytic) aims to reduce
the multiplication of parasites once they have entered the blood. A third type of
vaccine (anti-toxic) does not aim to reduce the parasites but aims to reduces the
toxins created by the parasites.1 Vaccines are also being investigated that combine
different components of these three types of vaccines. Figure 2 depicts how the
vaccine can affect the parasites’ development in the liver, the parasites’ replication
in the blood and the parasites’ release of toxins by the lines between the vaccine
1Some of the parasites in the blood move to a dormant stage. If a mosquito bites a person with
the parasites, the dormant parasite continue their life cycle in the mosquito and then can infect a
new person when the mosquito bites a new person. A fourth type of vaccine (transmission blocking)
targets the dormant parasites in the bloodstream. It does not help the person with malaria herself but
aims to reduce transmission in the community.
and the boxes representing each of these three stages of parasite activity. For a
good review of recent work on malaria vaccines, see Girard et al. (2007).
Other infections that causes fever, such as common cold, pneumonia, in-
fluenza, viral hepatitis or typhoid fever, are depicted by the box on the top of Figure
2 as non-malaria infections. There may be unmeasured common causes between
the non-malaria infections and any stage of parasite development. For example,
there may be unmeasured socioeconomic variables that make a child more vulner-
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able to being bit by a mosquito carrying malaria parasites (e.g., a family with low
socioeconomic status may be less likely to purchase a bed net) and more vulnerable
to non-malaria infections.
As discussed in Section 2, it is possible that the vaccine causes non-malaria
infections and non-malaria caused fevers. This is reflected in Figure 2 by the lines
between the vaccine box and the non-malaria infections and fever boxes.
One additional causal relationship that is depicted in Figure 2 is that fever
itself causes a reduction in parasite density; this is depicted by the line between
the fever box and the parasites replicate box. There is in vitro evidence that high
temperatures inhibit parasite growth (Kwiatkowski, 1989; Long et al., 2000) and in
vivo evidence that parasite density is suppressed during the febrile illnesses measles
and influenza (Rooth and Bjorkman, 1992).
4 Estimators of Vaccine Efficacy
We discuss the properties of the two currently used approaches to estimating vac-
cine efficacy. Both consist of substituting estimates of RP by malaria and RV by
malaria into (2) for V E∗. Recall that under assumption (A-1), V E∗ is equal to V E.
Both approaches estimate RP by malaria and RV by malaria by using a “case defini-
tion” of a malaria caused fever: the first method uses a deterministic case definition
while the second method uses a probabilistic case definition.
4.1 Deterministic Case Definition
The most commonly used deterministic case definition of malaria caused fever is the
conjunction of fever and a parasite density above a cutoff c. For example, Alonso et
al. (2004) and Bejon et al. (2008) used a cutoff of 2,500 parasites per µl and Sagara
et al. (2009) used a cutoff of 3,000 parasites per µl. Because of variation in nat-
ural and acquired immunity, there is considerable variation in children’s pyrogenic
thresholds, the minimum parasite density at which the parasites will cause a child
to have a fever (Marsh, 2002). Consequently a case definition of the conjunction
2
Using the definition of malaria caused fever in Section 2, the child would only be a false negative
if she does not also have another fever causing infection.
of fever and parasite density above 2,500 µl will include some false positives, chil-
dren who have a fever and a parasite density above 2,500 µl but who are tolerating
the parasites and only have a fever because of another infectious agent. The case
definition will also miss some false negatives, children whose pyrogenic thresh-
old and actual parasite density is below 2,500 but who have parasite densities that
are greater than their pyrogenic thresholds and thus have fevers that are caused by
malaria parasites.2
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Figure 2: Causal Diagram of the Effects of Vaccine and Other Causes on Fever
Rogers et al. (2006) and Smith (2007) study the use of case definitions of
the conjunction of fever and parasite density above a certain cutoff c for estimat-
ing vaccine efficacy. Both papers show in simulation studies that estimated vaccine
efficacies depend heavily on the cutoff. Here, we present a formula for the asymp-
totic bias of the estimator ˆV E(c) that uses the deterministic case definition of the
conjunction of fever and a parasite density above c. As the sample size from a
randomized trial converges to ∞, ˆV E(c) converges in probability to
V E(c) = 1− P(Y
(v) = 1,D(v) > c)
P(Y (p) = 1,D(p) > c)
,
where D(v) and D(p) denote the potential parasite densities under the vaccine and
placebo respectively. Let SEP be the sensitivity of the cutoff c for detecting malaria-
caused fevers under the placebo, SEP = P(D(p) > c|Y (p) = 1,Y (e) = 0); SPP be the
specificity of the cutoff c for detecting non-malaria caused fevers under the placebo,
SPP = P(D(p) ≤ c|Y (p) = 1,Y (e) = 1); SEV be the sensitivity under the vaccine,
7
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SEV = P(D(v) > c|Y (v) = 1,Y (e) = 0); and SPV be the specificity under the vaccine,
SPV = P(D(v) ≤ c|Y (v) = 1,Y (e) = 1). Then,
V E(c) =
1−
P(Y (v) = 1,Y (e) = 0)+P(Y (v) = 1,Y (e) = 1,D(v) > c)−P(Y (v) = 1,Y (e) = 0,D(v) ≤ c)
P(Y (p) = 1,Y (e) = 0)+P(Y (p) = 1,Y (e) = 1,D(p) > c)−P(Y (p) = 1,Y (e) = 0,D(p) ≤ c) =
1− P(Y
(v) = 1,Y (e) = 0)(SPV +SEV −1)+P(Y (v) = 1)(1−SPV )
P(Y (p) = 1,Y (e) = 0)(SPP+SEP−1)+P(Y (p) = 1)(1−SPP)
.
Under assumption (A-1) that the vaccine does not cause fevers, the asymptotic bias
of V E(c) is
V E(c)−V E =
P(Y (v) = 1,Y (e) = 0)
P(Y (p) = 1,Y (e) = 0)
− P(Y
(v) = 1,Y (e) = 0)(SPV +SEV −1)+P(Y (v) = 1)(1−SPV )
P(Y (p) = 1,Y (e) = 0)(SPP+SEP−1)+P(Y (p) = 1)(1−SPP)
.
The WHO Study Group on Measures of Malaria Vaccine Efficacy (Moorthy
et al., 2007) recommended choosing the cutoff c so that the specificity is at least 0.8.
However, the asymptotic bias depends on the specificity and sensitivity under both
the placebo and vaccine arms. Furthermore, the variance of ˆV E(c) is a complicated
function of θ = (P(Y (v) = 1,Y (e) = 0), P(Y (p) = 1,Y (e) = 0), SPV , SEV , SPP,SEP).
Therefore, we recommend that if a deterministic cutoff is used, it should be chosen
based on considering the estimated root mean squared error and power under a
preliminary estimate(s) of θ . This is illustrated in Section 6 (see Figure 8).
4.2 Using Probabilistic Case Definitions to Estimate Vaccine Ef-
ficacy
Rogers et al. (2006) and Smith (2007) suggest as an alternative to using an imper-
fect, deterministic case definition of a malaria caused fever to instead estimate the
probability that a fever was caused by malaria and use these estimated probabilities
to estimate RP and RV .
Smith, Schellenberg and Hayes (1994) proposed the following probabilistic
case definition of malaria caused fever: if child i on the placebo arm has a fever,
then the probability that it is malaria caused is
pi =
P(Y (p)i = 1|D = Di,X = Xi)−P(Y (p)i = 1|D = 0,X = Xi)
P(Y (p)i = 1|D = Di,X = Xi)
, (3)
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where Xi are measured covariates such as age and season and Di is measured para-
site density. The same case definition holds for the vaccine arm with Y (v)i replacing
Y (p)i in (3). The intuition behind (3) is the following: (a) all fevers for children with
D = 0 are assumed to come from non-malaria fever causing infections; (b) if para-
site densities Di are independent of non-malaria infections conditional on Xi, then
the probability of a non-malaria fever causing infection for a child with D = Di is
the same as for a child with D = 0 and thus equals P(Y (p)i = 1|D = 0,X = Xi); (c)
thus, the difference between the probability of a fever given D = Di and the proba-
bility of a fever given D = 0 represents the proportion of children with D = Di and
X = Xi who have malaria caused fever. Small (2009) provides more discussion.
A key assumption for (3) to provide the correct probability of child i having
a malaria caused fever is that the parasite densities Di are independent of non-
malaria fever causing infections conditional on Xi. However, Figure 2 suggests that
this is not likely to be true. First, there is the problem of unmeasured common
causes of parasite densities and non-malaria infections. Second, there is the prob-
lem that fever due to any cause kills parasites. The consequence of parasites being
killed by fever is that children with non-malaria fever causing infections tend to
have lower parasite density than children without non-malaria fever causing infec-
tions.
5 Simulation Study
In our simulation study, we will consider four important factors that may affect the
performance of estimators of vaccine efficacy:
1. Type of vaccine: The two most common types of vaccines that are being de-
veloped are (1) pre-erythrocytic (pre-blood stage) vaccines that seek to pre-
vent the malaria parasites from entering an infected person’s blood; (2) ery-
throcytic (blood stage) vaccines that seek to slow the replication of malaria
parasites after the parasites have entered the blood (Girard et al., 2007). Smith
(2007) found that the type of vaccine affected the performance of different
estimators. Following Smith, we will consider one pre-erythrocytic stage
vaccine and one erythrocytic vaccine:
• Pre-erythrocytic (pre-blood stage) vaccine. This vaccine eliminates 50%
of malaria infections. For simplicity, this is assumed to be reflected in a
50% reduction in the proportion of children who are infected across the
range of parasite densities.
• Erythrocytic (blood stage) vaccine. This vaccine reduces parasite densi-
ties by 50% but does not affect the number of children who are infected.
9
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2. Endemicity: Areas differ greatly in how endemic the malaria parasites are,
i.e., how high the rate of infection with malaria parsites is. This could have a
substantial impact on various estimators, in particular the deterministic case
definition estimators since the specificity and sensitivity of the case defini-
tion varies with the endemicity. We consider three levels of endemicity:
mesoendemic (low to moderate), hyperendemic (medium high) and holoen-
demic (high). We define specifically the levels of endemicity we consider
below.
3. Effect of fever on parasites: One reason that the probabilistic case definition
estimators of vaccine efficacy may be biased is that fever due to any cause
kills parasites, as discussed in Section 3. Although there is both in vitro and
in vivo evidence for this phenomenon, as cited in Section 3, there are no
definitive studies of the proportion of parasites that fever kills in field set-
tings. Long et al. (2001) estimated that in vitro, parasite growth was reduced
by 50% at 101.8◦F and 92% at 104◦F. We consider three ranges of effect
of fever on parasites: large fever effect (fever kills approximately 90% of
parasites), moderate fever effect (fever kills approximately 50% of parasites)
and no fever effect (fever kills no parasites). Although we do not think the
no effect assumption is realistic, we include it for comparison because most
previous work on malaria vaccine efficacy has assumed no effect.
4. Sample size: We consider two sample sizes, 1,000 children on each arm and
10,000 children on each arm. Preliminary explorations indicated that the es-
timators differed in their finite sample biases.
We conduct a 2× 3× 3× 2 factorial experiment to investigate the effect of these
factors on the performance of different estimators of vaccine efficacy.
Figure 3 describes our simulation study in a causal diagram. Specifically,
we generate the data as follows:
1. We randomly assign n children to the placebo and n children to the vaccine
arm (either the pre-erythrocytic or erythrocytic vaccine), where n = 1,000 or
n = 10,000.
2. A child can get fever through two sources: malaria infection (MI) or non-
malaria infection (NMI). Let Y MIi = 1 if child i has a malaria infection strong
enough to cause a fever, 0 if not and Y NMIi = 1 if child i has a non-malaria in-
fection strong enough to cause a fever, 0 if not. The non-malaria and malaria
infections are assumed to operate like parallel circuits in causing a fever so
that child i is observed to have a fever, Yi = 1, if and only if Y MIi +Y
NMI
i ≥ 1.
3. Let Di be child i’s observed parasite density and DNo.NMIi be the parasite den-
sity that child i would have if the child did not have a non-malaria infection
10
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Figure 3: Causal diagram describing the simulation study.
strong enough to cause a fever. Di might not equal DNo.NMIi because fever can
kill parasites. We can think of DNo.NMIi as the parasitological challenge faced
by the child that arises from the amount that malaria-carrying mosquitoes bite
the child and the immune response of the child. We assume that Di =DNo.NMIi
unless Y NMIi = 1,Y
MI
i = 0. This is because when Y
NMI
i = 1,Y
MI
i = 1 or
Y NMIi = 0,Y
MI
i = 1, then child i would have a fever even if she did not have a
non-malaria infection and so the effect of fever killing parasites on the child
would be the same in a world without non-malaria infections as in the actual
world so that Di = DNo.NMIi ; also, if Y
NMI
i = 0,Y
MI
i = 0, then child i would
not have a fever in both a world without non-malaria infections and the actual
world so that fever killing parasites has no effect in either world and con-
sequently Di = DNo.NMIi . When Y
NMI
i = 1,Y
MI
i = 0, then in the absence of a
non-malaria infection, child i would not have a fever and then parasites would
not have been killed by the fever so that DNo.NMIi might be greater than Di.
The effect of fever on parasite density is represented by the arrow from fever
to parasite density in Figure 3. We consider three magnitudes of effect of
fever on parasite density:
• No fever effect: Di = DNo.NMIi when Y NMIi = 1,Y MIi = 0.
• Moderate fever effect: Di = kiDNo.NMIi when Y NMIi = 1,Y MIi = 0 where
ki ∼ Beta(5,5), i.e., on average, fever kills 50% of parasites.
• Large fever effect: Di = kiDNo.NMIi when Y NMIi = 1,Y MIi = 0 where ki ∼
Beta(1,9), i.e., on average, fever kills 90% of parasites.
4. The probability that DNMIi = 0 is determined by the endemicity level. We
consider three levels of endemicity:
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• Holoendemic: The probability that a child is infected with malaria par-
asites in the placebo arm is 0.8.
• Hyperendemic: The probability that a child is infected with malaria
parasites in the placebo arm is 0.5.
• Mesoendemic: The probability that a child is infected with malaria par-
asites in the placebo arm is 0.2.
For children infected with malaria parasites, we assume that the distribution
of DNMIi is that shown in Figure 4. This distribution was chosen to approxi-
mate the distribution found in a study in the Kilombero District (Morogoro)
Region of Tanzania that was analyzed in Smith, Schellenberg and Hayes
(1994).
5. Based on the estimates of the probability of malaria caused fever in Smith,
Schellenberg and Hayes (1994) for the study mentioned above in the Kilo-
mbero District of Tanzania, we set P(Y NMIi ) = 0.06 and
P(Y MIi |DNo.NMIi ) =
exp(.000027DNo.NMIi )
1+ exp(.000027DNo.NMIi )
.
The P(Y MIi ) and P(Y
NMI
i ) are plotted in Figure 5.
The R code for our simulation study is available from the authors.
We consider five estimators of vaccine efficacy: (1) deterministic case def-
inition set so that the specificity of the case definition under the placebo is 0.7;
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Figure 4: Probability Density of DNMI conditional on a child being infected
(DNMI > 0) under the placebo.
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(2) deterministic case definition set so that the specificity of the case definition un-
der the placebo is 0.8; (3) deterministic case definition set so that the specificity
under the placebo is 0.9; (4) deterministic case definition with a cutoff of 2,500
parasites per µl, this is the cutoff used by Alonso et al. (2004) and Bejon et al.
(2008); (5) probabilistic case definition using the correct logistic regression model
for P(Yi = 1|Di) when there is no effect of fever killing parasites.
The simulation results are shown in Figure 6 (pre-erythrocytic vaccine) and
Figure 7 (erythrocytic vaccine). Abs. Prop. Bias is is the absolute proportion bias,
i.e., the absolute bias of the estimator divided by the true value of V E. The true
values of V E ranged from 0.46 to 0.64. In the figures, we only show the bias and
RMSE up to a maximum of 0.7. Complete numerical results are available from the
authors.
Our main findings are the following:
• Performance of WHO’s recommended approach: For the pre-erythrocytic
vaccine, the WHO’s recommended approach of choosing a deterministic cut-
off so that the specificity is 0.8 (under the placebo) generally worked well,
with biases of at most 15%, and RMSE less than the probabilistic case def-
inition estimator for all settings. However, for the erythrocytic vaccine, the
WHO’s recommended approach sometimes worked very poorly, with biases
over 70% for some settings. For the erythrocytic vaccine, the RMSE of the
0 20000 40000 60000 80000 100000 120000
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Parasite Density
Pr
ob
ab
ilit
y 
of
 F
ev
e
r
P(YMI = 1|DNo.NMI)
P(YNMI = 1|DNo.NMI)
Figure 5: P(Y MI = 1|DNo.NMI) and P(Y NMI = 1|DNo.NMI)
WHO’s recommended approach was sometimes better and sometimes worse
than that of the probabilistic case definition estimator.
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• Comparison of deterministic case definitions of different specificities: For
most settings, the estimators based on deterministic case definitions set to
have specificities 0.7, 0.8 and 0.9 performed similarly. For the pre-erythrocytic
vaccine in the mesoendemic setting with no or moderate fever effects and
n = 1,000, the specificity 0.7 and 0.8 estimators were somewhat better than
the specificity 0.9 estimator. However, for these same settings for the ery-
throcytic vaccine, the specificity 0.9 estimator was somewhat better than
the specificity 0.7 and 0.8 estimators (not only for n = 1,000 but also for
n = 10,000). The specificity 0.9 estimator was also somewhat better than
the 0.7 and 0.8 estimators for the erythrocytic vaccine in the hyperendemic
settings with n = 10,000.
• Performance of cutoff of 2,500 parasites per µl: For the pre-erythrocytic
vaccine, the deterministic cutoff of 2,500 parasites per µl worked reasonably
well in the holoendemic and hyperendemic settings, but did not work well for
mesoendemic settings with sample size n = 1,000 per arm, especially when
there was a large fever effect. For the erythrocytic vaccine, the determinis-
tic cutoff of 2,500 also performed poorly in these settings. In addition, for
the erythrocytic vaccine, the deterministic cutoff of 2,500 was substantially
worse than the WHO’s recommended approach for the holoendemic setting
with no fever effect for both n = 1,000 and n = 10,000 and for the holoen-
demic setting with a moderate fever effect for n = 1,000.
• Finite sample bias of probabilistic case definition estimator: The probabilis-
tic case definition estimator sometimes exhibited large finite sample biases
for n = 1,000 that were reduced substantially for n = 10,000. When there
is no fever effect, the probabilistic case definition estimator is consistent; see
Section 4.2. The consistency is apparent for n = 10,000 for which the biases
of the probabilistic case definition estimator when there is no fever effect are
all less than 5%. However, for n = 1,000, the biases were sometimes large,
above 70% for the pre-erythrocytic vaccine in the mesoendemic setting and
above 10% for the pre-erythrocytic vaccine in the holoendemic and hyperen-
demic settings and for the erythrocytic vaccine in the mesoendemic setting.
6 Discussion
We have provided a potential outcomes definition of the efficacy of a malaria vac-
cine and studied the properties of two methods for estimating the efficacy, (1) using
an imperfect deterministic case definition of the conjunction of fever and parasite
density above a certain cutoff and (2) using a probabilistic case definition that aims
to estimate the probability that a child with fever has a malaria caused fever. We
have shown that both methods potentially have large biases.
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Figure 6: Simulation results for pre-erythrocytic vaccine. Bias is the absolute pro-
portion bias. If the bias or RMSE was above 0.7, only a maximum of 0.7 is shown
in the plots.
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Figure 7: Simulation results for erythrocytic vaccine. Bias is the absolute propor-
tion bias. If the bias or RMSE was above 0.7, only a maximum of 0.7 is shown in
the plots.
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Figure 8: RMSE and proportion biases for different cutoffs for erythrocytic vac-
cines in a holoendemic area under the assumption of a moderate fever killing effect
with a sample size of n = 1,000 per arm.
To choose an estimator that will be used for the primary analysis in a clin-
ical trial, we suggest that the performance of different estimators over a range of
a different vaccine efficacies be considered. For example, consider an erythrocytic
vaccine for a holoendemic area under the assumption of a moderate fever killing
effect with a sample size of n = 1,000 per arm. Figure 8 plots the RMSEs and pro-
portion bias of the the deterministic case definition estimators with cutoffs ranging
from 100 to 10,000 parasites per µl for three vaccines of different efficacies: one
vaccine reduces parasite density by 20%, another by 50% and another by 80%. For
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vaccines covering this range of efficacies, the cutoff of 2,500 is a reasonable choice
– it has about the smallest RMSE over different cutoffs for the vaccines that reduce
parasite density by 20% and 50%, and is only a little above the minimum RMSE
for the vaccine that reduces parasite density by 80%.
In addition to choosing one estimator for a primary analysis, a useful sec-
ondary analysis is to conduct a sensitivity analysis that displays a range of efficacy
estimates over a range of plausible assumptions about how unmeasured common
causes affect parasite density and non-malaria infections and how much of an effect
fever has on killing parasites. Further work needs to be done in developing such
sensitivity analyses
An additional important issue which we have not discussed in this paper is
measurement error in parasite density. O’Meara, Hall and McKenzie (2007) discuss
the difficulties created by measurement error.
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